Anti-PLMN/ PLG monoclonal antibody
Anti-PLMN/ PLG antibody for FACS & in-vivo assay
Go to PLG/PLG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T89034-Ab-1/ GM-Tg-hg-T89034-Ab-2 | Anti-Human PLG monoclonal antibody | Human |
GM-Tg-rg-T89034-Ab-1/ GM-Tg-rg-T89034-Ab-2 | Anti-Rat PLG monoclonal antibody | Rat |
GM-Tg-mg-T89034-Ab-1/ GM-Tg-mg-T89034-Ab-2 | Anti-Mouse PLG monoclonal antibody | Mouse |
GM-Tg-cynog-T89034-Ab-1/ GM-Tg-cynog-T89034-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PLG monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T89034-Ab-1/ GM-Tg-felg-T89034-Ab-2 | Anti-Feline PLG monoclonal antibody | Feline |
GM-Tg-cang-T89034-Ab-1/ GM-Tg-cang-T89034-Ab-2 | Anti-Canine PLG monoclonal antibody | Canine |
GM-Tg-bovg-T89034-Ab-1/ GM-Tg-bovg-T89034-Ab-2 | Anti-Bovine PLG monoclonal antibody | Bovine |
GM-Tg-equg-T89034-Ab-1/ GM-Tg-equg-T89034-Ab-2 | Anti-Equine PLG monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T89034-Ab-1/ GM-Tg-hg-T89034-Ab-2; GM-Tg-rg-T89034-Ab-1/ GM-Tg-rg-T89034-Ab-2; GM-Tg-mg-T89034-Ab-1/ GM-Tg-mg-T89034-Ab-2; GM-Tg-cynog-T89034-Ab-1/ GM-Tg-cynog-T89034-Ab-2; GM-Tg-felg-T89034-Ab-1/ GM-Tg-felg-T89034-Ab-2; GM-Tg-cang-T89034-Ab-1/ GM-Tg-cang-T89034-Ab-2; GM-Tg-bovg-T89034-Ab-1/ GM-Tg-bovg-T89034-Ab-2; GM-Tg-equg-T89034-Ab-1/ GM-Tg-equg-T89034-Ab-2 |
Products Name | Anti-PLG monoclonal antibody |
Format | mab |
Target Name | PLG |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-PLG benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species PLMN/ PLG VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLPm004371 | mouse Plg Lentivirus plasmid |
ORF Viral Vector | vGMLPm004371 | mouse Plg Lentivirus particle |
Target information
Target ID | GM-T89034 |
Target Name | PLG |
Gene ID | 5340,18815,85253,703891,403602,101095261,280897,100050531 |
Gene Symbol and Synonyms | Ab1-346,HAE4,LPA,Pg,PLG |
Uniprot Accession | P00747,Q01177,P12545,P80009,P06868,P80010 |
Uniprot Entry Name | PLMN_HUMAN,PLMN_MACMU,PLMN_RAT,PLMN_CANLF,PLMN_BOVIN,PLMN_HORSE |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | Acute appendicitis, Nephrotic syndrome |
Gene Ensembl | ENSG00000122194 |
Target Classification | N/A |
The target: PLG, gene name: PLG, also named as . The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.